Zhang Liang, Luerken Lukas, Mayr Vinzenz, Goetz Andrea, Schlitt Alexandra, Stroszczynski Christian, Einspieler Ingo
Department of Radiology, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
Cancers (Basel). 2024 Dec 18;16(24):4211. doi: 10.3390/cancers16244211.
: To evaluate the efficacy and safety of the Surgnova Dophi™ M150E microwave ablation system in a prospective single-center observational study. : A cohort of 50 patients with 77 primary or secondary liver tumors underwent CT-navigated stereotactic percutaneous microwave ablation with curative intention using the Surgnova Dophi™ M150E system. The endpoints were primary technique efficacy (PTE), number of complications, ablation defect dimensions, and sphericity index compared to previously reported findings. : The PTE was 97.4%, with complete ablation in 75 out of 77 tumors. Complications occurred in 10% of patients, with 4% classified as major. A comparison with previous in vivo data confirmed the reliability of the system in achieving reproducible and predictable ablation results. : Stereotactic percutaneous microwave ablation with the Surgnova Dophi™ M150E system is safe and effective for liver tumor treatment.
在一项前瞻性单中心观察性研究中评估Surgnova Dophi™ M150E微波消融系统的有效性和安全性。一组50例患有77个原发性或继发性肝肿瘤的患者使用Surgnova Dophi™ M150E系统在CT引导下进行立体定向经皮微波消融,目的是治愈。终点指标为主要技术疗效(PTE)、并发症数量、消融缺损尺寸和球形指数,并与先前报道的结果进行比较。PTE为97.4%,77个肿瘤中有75个完全消融。10%的患者发生并发症,4%为严重并发症。与先前的体内数据比较证实了该系统在实现可重复和可预测的消融结果方面的可靠性。使用Surgnova Dophi™ M150E系统进行立体定向经皮微波消融治疗肝肿瘤是安全有效的。